This phase III trial is trying to determine how well combination chemotherapy works in treating young patients with newly diagnosed B-Cell Acute Lymphoblastic Leukaemia that is likely to come back or spread.
This trial is treating patients with Acute Lymphoblastic Leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT02883049
- NCI-2011-03797, CDR0000706370, U10CA098543, COG-AALL1131, AALL1131
Scientific Title
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine in the Very High Risk Stratum
Cooperative Group
Children's Oncology Group
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
PURPOSE: This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed high-risk acute lymphoblastic leukemia.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More